Abstract
The conventional method of one drug being used for one target has not yielded therapeutic solutions for Lewy body dementia (LBD), which is a leading progressive neurological disorder characterized by significant loss of neurons. The age-related disease is marked by memory loss, hallucinations, sleep disorder, mental health deterioration, palsy, and cognitive impairment, all of which have no known effective cure. The present study deploys a network medicine pipeline to repurpose drugs having considerable effect on the genes and proteins related to the diseases of interest. We utilized the novel SAveRUNNER algorithm to quantify the proximity of all drugs obtained from DrugBank with the disease associated gene dataset obtained from Phenopedia and targets in the human interactome. We found that most of the 154 FDA-approved drugs predicted by SAveRUNNER were used to treat nervous system disorders, but some off-label drugs like quinapril and selegiline were interestingly used to treat hypertension and Parkinson’s disease (PD), respectively. Additionally, we performed gene set enrichment analysis using Connectivity Map (CMap) and pathway enrichment analysis using EnrichR to validate the efficacy of the drug candidates obtained from the pipeline approach. The investigation enabled us to identify the significant role of the synaptic vesicle pathway in our disease and accordingly finalize 8 suitable antidepressant drugs from the 154 drugs initially predicted by SAveRUNNER. These potential anti-LBD drugs are either selective or non-selective inhibitors of serotonin, dopamine, and norepinephrine transporters. The validated selective serotonin and norepinephrine inhibitors like milnacipran, protriptyline, and venlafaxine are predicted to manage LBD along with the affecting symptomatic issues.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
Supplementary data is available with the manuscript.
References
Aggarwal S, Mortensen OV (2017) Overview of monoamine transporters. Curr Protoc Pharmacol 79:12.16.1-12.16.17. https://doi.org/10.1002/cpph.32
Ahsan MJ, Ali A, Ali A, Thiriveedhi A, Bakht MA, Yusuf M, Salahuddin Afzal, O., & Altamimi, A. S. A. (2022) Pyrazoline containing compounds as therapeutic targets for neurodegenerative disorders. ACS Omega 7(43):38207–38245. https://doi.org/10.1021/acsomega.2c05339
Barabási AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet 12(1):56–68. https://doi.org/10.1038/nrg2918
Beckstead, R.M. (1996). The life cycle of neurotransmitters. In: A survey of medical neuroscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8570-5_3
Breuer K, Foroushani AK, Laird MR, Chen C, Sribnaia A, Lo R, Winsor GL, Hancock RE, Brinkman FS, Lynn DJ (2013) InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res 41(Database issue):D1228–D1233. https://doi.org/10.1093/nar/gks1147
Caldera M, Buphamalai P, Müller F, Menche J (2017) Interactome-based approaches to human disease. Curr Opin Syst Biol 3:88–94. https://doi.org/10.1016/j.coisb.2017.04.015
Calo L, Wegrzynowicz M, Santivañez-Perez J, Grazia Spillantini M (2016) Synaptic failure and α-synuclein. Movement disorders : official journal of the Movement Disorder Society 31(2):169–177. https://doi.org/10.1002/mds.26479
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D (2018) Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 175(2):168–180. https://doi.org/10.1111/bph.13798
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma’ayan A (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128. https://doi.org/10.1186/1471-2105-14-128
Cheng F, Desai RJ, Handy DE, Wang R, Schneeweiss S, Barabási AL, Loscalzo J (2018) Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun 9(1):2691. https://doi.org/10.1038/s41467-018-05116-5
Cheng F, Lu W, Liu C, Fang J, Hou Y, Handy DE, Wang R, Zhao Y, Yang Y, Huang J, Hill DE, Vidal M, Eng C, Loscalzo J (2019) A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat Commun 10(1):3476. https://doi.org/10.1038/s41467-019-10744-6
Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, Walton RL, Ahmed S, Viollet C, Ding J, Makarious MB, Diez-Fairen M, Portley MK, Shah Z, Abramzon Y, Hernandez DG, Blauwendraat C, Stone DJ, Eicher J, Parkkinen L, Scholz SW (2021) Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet 53(3):294–303. https://doi.org/10.1038/s41588-021-00785-3
Clough E, Barrett T (2016) The Gene Expression Omnibus database. Methods Mol Biol (Clifton, N.J.) 1418:93–110. https://doi.org/10.1007/978-1-4939-3578-9_5
Colom-Cadena M, Pegueroles J, Herrmann AG, Henstridge CM, Muñoz L, Querol-Vilaseca M, Martín-Paniello CS, Luque-Cabecerans J, Clarimon J, Belbin O, Núñez-Llaves R, Blesa R, Smith C, McKenzie CA, Frosch MP, Roe A, Fortea J, Andilla J, Loza-Alvarez P, Gelpi E, Lleó A (2017) Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain : a journal of neurology 140(12):3204–3214. https://doi.org/10.1093/brain/awx275
Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, Biankin AV, Hautaniemi S, Wu J (2012) PINA v2.0: mining interactome modules. Nucleic Acids Res 40(Database issue):D862–D865. https://doi.org/10.1093/nar/gkr967
Purves D, Augustine GJ, Fitzpatrick D et al. (eds) (2001) Neuroscience. 2nd edition. Sunderland (MA): Sinauer Associates.Available from: https://www.ncbi.nlm.nih.gov/books/NBK10799/
Dudley JT, Deshpande T, Butte AJ (2011) Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 12(4):303–311. https://doi.org/10.1093/bib/bbr013
Fereshtehnejad SM, Damangir S, Cermakova P, Aarsland D, Eriksdotter M, Religa D (2014) Comorbidity profile in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. Alzheimer's research & therapy 6(5–8):65. https://doi.org/10.1186/s13195-014-0065-2
Ferman TJ, Boeve BF, Smith GE, Silber MH, Lucas JA, Graff-Radford NR, Dickson DW, Parisi JE, Petersen RC, Ivnik RJ (2002) Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. Journal of the International Neuropsychological Society : JINS 8(7):907–914. https://doi.org/10.1017/s1355617702870047
Fiscon G, Paci P (2021) SAveRUNNER: an R-based tool for drug repurposing. BMC Bioinformatics 22(1):150. https://doi.org/10.1186/s12859-021-04076-w
Fiscon G, Conte F, Farina L, Paci P (2021) SAveRUNNER: a network-based algorithm for drug repurposing and its application to COVID-19. PLoS Comput Biol 17(2). https://doi.org/10.1371/journal.pcbi.1008686
Fiscon G, Sibilio P, Funari A, Conte F, Paci P (2022) Identification of potential repurposable drugs in Alzheimer’s disease exploiting a bioinformatics analysis. Journal of personalized medicine 12(10):1731. https://doi.org/10.3390/jpm12101731
Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D (2011) Depressive symptoms in Alzheimer’s disease and Lewy body dementia: a one-year follow-up study. Dement Geriatr Cogn Disord 32(2):143–149. https://doi.org/10.1159/000332016
Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL (2007) The human disease network. Proc Natl Acad Sci USA 104(21):8685–8690. https://doi.org/10.1073/pnas.0701361104
Hakimi M, Maurer CW (2019) Pseudobulbar affect in Parkinsonian disorders: a review. Journal of movement disorders 12(1):14–21. https://doi.org/10.14802/jmd.18051
Hatzopoulos AK (2019) Disease models & mechanisms in the age of big data. Disease models & mechanisms 12(8):dmm041699. https://doi.org/10.1242/dmm.041699
Henstridge CM, Pickett E, Spires-Jones TL (2016) Synaptic pathology: a shared mechanism in neurological disease. Ageing Res Rev 28:72–84. https://doi.org/10.1016/j.arr.2016.04.005
Hopkins A (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682–690. https://doi.org/10.1038/nchembio.118
Jung YJ, Tweedie D, Scerba MT, Greig NH (2019) Neuroinflammation as a factor of neurodegenerative disease: thalidomide analogs as treatments. Frontiers in cell and developmental biology 7:313. https://doi.org/10.3389/fcell.2019.00313
Kane JPM, Surendranathan A, Bentley A, Barker SAH, Taylor JP, Thomas AJ, Allan LM, McNally RJ, James PW, McKeith IG, Burn DJ, O’Brien JT (2018) Clinical prevalence of Lewy body dementia. Alzheimer's research & therapy 10(1):19. https://doi.org/10.1186/s13195-018-0350-6
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1):D353–D361. https://doi.org/10.1093/nar/gkw1092
Karaman B, Sippl W (2019) Computational drug repurposing: current trends. Curr Med Chem 26(28):5389–5409. https://doi.org/10.2174/0929867325666180530100332
Kowshik AV, Manoj M, Sowmyanarayan S, Chatterjee J (2023) Drug repurposing: databases and pipelines.CNS Spectrums, 1–4. Advance online publication. https://doi.org/10.1017/S1092852923002365
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma’ayan A (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44(W1):W90–W97. https://doi.org/10.1093/nar/gkw377
Lam B, Hollingdrake E, Kennedy JL, Black SE, Masellis M (2009) Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: the emerging pharmacogenetic story. Hum Genomics 4(2):91–106. https://doi.org/10.1186/1479-7364-4-2-91
Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, N.Y.) 313(5795):1929–1935. https://doi.org/10.1126/science.1132939
Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E, Castagnoli L, Cesareni G (2012) MINT, the molecular interaction database: 2012 update. Nucleic Acids Res 40(Database issue):D857–D861. https://doi.org/10.1093/nar/gkr930
Londos E (2018) Practical treatment of Lewy body disease in the clinic: patient and physician perspectives. Neurology and therapy 7(1):13–22. https://doi.org/10.1007/s40120-017-0090-8
Luck K, Kim DK, Lambourne L, Spirohn K, Begg BE, Bian W, Brignall R, Cafarelli T, Campos-Laborie FJ, Charloteaux B, Choi D, Coté AG, Daley M, Deimling S, Desbuleux A, Dricot A, Gebbia M, Hardy MF, Kishore N, Knapp JJ, Calderwood MA (2020) A reference map of the human binary protein interactome. Nature 580(7803):402–408. https://doi.org/10.1038/s41586-020-2188-x
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., Dickson, D., Dubois, B., Duda, J. E., Feldman, H., Gauthier, S., Halliday, G., Lawlor, B., Lippa, C., Lopez, O. L., Carlos Machado, J., O’Brien, J., Playfer, J., Reid, W., & International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. The Lancet. Neurology 3(1):19–28. https://doi.org/10.1016/s1474-4422(03)00619-7
Mizutani M, Sano T, Ohira M, Takao M (2022) Neuropathological studies of serotonergic and noradrenergic systems in Lewy body disease patients with delusion or depression. Psychiatry Clin Neurosci 76(9):459–467. https://doi.org/10.1111/pcn.13436
Morselli Gysi D, do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., & Barabási, A. L. (2021) Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci USA 118(19). https://doi.org/10.1073/pnas.2025581118
Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66–79. https://doi.org/10.1016/j.neuron.2009.12.023
Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt HHHW (2022) Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci 43(2):136–150. https://doi.org/10.1016/j.tips.2021.11.004
Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, Chavali G, Chen C, del-Toro, N., Duesbury, M., Dumousseau, M., Galeota, E., Hinz, U., Iannuccelli, M., Jagannathan, S., Jimenez, R., Khadake, J., Lagreid, A., Licata, L., … Hermjakob, H. (2014) The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res 42(Database issue):D358–D363. https://doi.org/10.1093/nar/gkt1115
Oughtred R, Stark C, Breitkreutz BJ, Rust J, Boucher L, Chang C, Kolas N, O’Donnell L, Leung G, McAdam R, Zhang F, Dolma S, Willems A, Coulombe-Huntington J, Chatr-Aryamontri A, Dolinski K, Tyers M (2019) The BioGRID interaction database: 2019 update. Nucleic Acids Res 47(D1):D529–D541. https://doi.org/10.1093/nar/gky1079
Palmieri I, Poloni TE, Medici V, Zucca S, Davin A, Pansarasa O, Ceroni M, Tronconi L, Guaita A, Gagliardi S, Cereda C (2022) Differential neuropathology, genetics, and transcriptomics in two kindred cases with Alzheimer’s disease and Lewy body dementia. Biomedicines 10(7):1687. https://doi.org/10.3390/biomedicines10071687
Paranjpe MD, Taubes A, Sirota M (2019) Insights into computational drug repurposing for neurodegenerative disease. Trends Pharmacol Sci 40(8):565–576. https://doi.org/10.1016/j.tips.2019.06.003
Patterson L, Rushton SP, Attems J, Thomas AJ, Morris CM (2019) Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain pathology (Zurich, Switzerland) 29(4):544–557. https://doi.org/10.1111/bpa.12697
Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, Muthusamy B, Gandhi TK, Chandrika KN, Deshpande N, Suresh S, Rashmi BP, Shanker K, Padma N, Niranjan V, Harsha HC, Talreja N, Vrushabendra BM, Ramya MA, Yatish AJ, Joy M, Pandey A (2004) Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res 32(Database issue):D497–D501. https://doi.org/10.1093/nar/gkh070
Power JH, Barnes OL, Chegini F (2017) Lewy bodies and the mechanisms of neuronal cell death in Parkinson’s disease and dementia with Lewy bodies. Brain pathology (Zurich, Switzerland) 27(1):3–12. https://doi.org/10.1111/bpa.12344
Reimand J, Isserlin R, Voisin V, Kucera M, Tannus-Lopes C, Rostamianfar A, Wadi L, Meyer M, Wong J, Xu C, Merico D, Bader GD (2019) Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA. Cytoscape and EnrichmentMap. Nature protocols 14(2):482–517. https://doi.org/10.1038/s41596-018-0103-9
Römer B, Dalen I, Ballard C, Aarsland D (2023) The course of depressive symptoms in Lewy body dementia and Alzheimer’s disease. J Affect Disord 333:459–467. https://doi.org/10.1016/j.jad.2023.04.076
Sanford AM (2018) Lewy body dementia. Clin Geriatr Med 34(4):603–615. https://doi.org/10.1016/j.cger.2018.06.007
Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog JE, Rocca WA (2013) Incidence of dementia with Lewy bodies and Parkinson disease dementia. JAMA Neurol 70(11):1396–1402. https://doi.org/10.1001/jamaneurol.2013.3579
Schulz-Schaeffer WJ (2010) The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol 120(2):131–143. https://doi.org/10.1007/s00401-010-0711-0
Sonawane AR, Weiss ST, Glass K, Sharma A (2019) Network medicine in the age of biomedical big data. Front Genet 10:294. https://doi.org/10.3389/fgene.2019.00294
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. https://doi.org/10.1073/pnas.0506580102
Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Golub TR (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171(6):1437-1452.e17. https://doi.org/10.1016/j.cell.2017.10.049
Sudhof TC (2004) The synaptic vesicle cycle. Annu Rev Neurosci 27:509–547. https://doi.org/10.1146/annurev.neuro.26.041002.131412
Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69(4):628–649. https://doi.org/10.1016/j.neuron.2011.02.010
Takahashi S, Mizukami K, Yasuno F, Asada T (2009) Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society 9(2):56–61. https://doi.org/10.1111/j.1479-8301.2009.00292.x
Talevi A, Bellera CL (2020) Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 15(4):397–401. https://doi.org/10.1080/17460441.2020.1704729
Vallortigara J, Rangarajan S, Whitfield D, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, Attems J, Ballard C, Thomas A, O’Brien J, Aarsland D, Francis P (2014) Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. F1000Research 3:108. https://doi.org/10.12688/f1000research.3786.1
van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, Lemstra AW (2020) Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer’s disease pathology: an 123I-FP-CIT SPECT study. NeuroImage. Clinical 25. https://doi.org/10.1016/j.nicl.2019.102062
Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet (London, England) 386(10004):1683–1697. https://doi.org/10.1016/S0140-6736(15)00462-6
Weintraub D, Hurtig HI (2007) Presentation and management of psychosis in Parkinson’s disease and dementia with Lewy bodies. Am J Psychiatry 164(10):1491–1498. https://doi.org/10.1176/appi.ajp.2007.07040715
Whitfield DR, Vallortigara J, Alghamdi A, Howlett D, Hortobágyi T, Johnson M, Attems J, Newhouse S, Ballard C, Thomas AJ, O’Brien JT, Aarsland D, Francis PT (2014) Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer’s disease: association with cognitive impairment. Neurobiol Aging 35(12):2836–2844. https://doi.org/10.1016/j.neurobiolaging.2014.06.015
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Wilson M (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074–D1082. https://doi.org/10.1093/nar/gkx1037
Yamada M, Komatsu J, Nakamura K, Sakai K, Samuraki-Yokohama M, Nakajima K, Yoshita M (2020) Diagnostic criteria for dementia with Lewy bodies: updates and future directions. Journal of movement disorders 13(1):1–10. https://doi.org/10.14802/jmd.19052
Yang SK, Chen W, Su CH, Liu CH (2018) Incidence and comorbidity of dementia with Lewy bodies: a population-based cohort study. Behav Neurol 2018:7631951. https://doi.org/10.1155/2018/7631951
Yu W, Gwinn M, Clyne M, Yesupriya A, Khoury MJ (2008) A navigator for human genome epidemiology. Nat Genet 40(2):124–125. https://doi.org/10.1038/ng0208-124
Yu W, Clyne M, Khoury MJ, Gwinn M (2010) Phenopedia and Genopedia: disease-centered and gene-centered views of the evolving knowledge of human genetic associations. Bioinformatics (Oxford, England) 26(1):145–146. https://doi.org/10.1093/bioinformatics/btp618
Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y, Chen Y (2022) Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. Nucleic Acids Res 50(D1):D1398–D1407. https://doi.org/10.1093/nar/gkab953
Zou L, Tian Y, Zhang Z (2021) Dysfunction of synaptic vesicle endocytosis in Parkinson’s disease. Front Integr Neurosci 15. https://doi.org/10.3389/fnint.2021.619160
Author information
Authors and Affiliations
Contributions
JC: conception of work, supervision, critical revision for important intellectual content, final approval of the manuscript version to be published. AK, SS, MM: conception of work, acquisition, analysis and interpretation of data for the work, manuscript preparation. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Ethics Approval
Study involves analysis of open-source dataset. No ethical approval is required.
Competing Interests
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Manoj, M., Sowmyanarayan, S., Kowshik, A.V. et al. Identification of Potentially Repurposable Drugs for Lewy Body Dementia Using a Network-Based Approach. J Mol Neurosci 74, 21 (2024). https://doi.org/10.1007/s12031-024-02199-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12031-024-02199-2